PFE - Arbutus Biopharma: A Wing And A Prayer

2025-03-28 09:48:31 ET

Summary

• Arbutus Biopharma just announced another significant restructuring, including layoffs and management changes, to reduce cash burn and streamline operations.
• The company is now focused on developing its sole drug candidate, imdusiran, which has shown promising early results in treating Hepatitis B.
• Analysts remain cautiously optimistic with several maintaining Buy ratings, but the stock's future hinges on imdusiran's success and ongoing patent litigation outcomes.
• An updated analysis around this clinical stage biopharma concern follows in the paragraphs below.

A lot has happened since I last put Arbutus Biopharma Corporation ( ABUS ) in the spotlight early last summer. This clinical stage biopharma concern. A few weeks after that article ran, the company was ending development of PD-L1 inhibitor AB-101, in phase 1 development to treat hepatitis B virus or HBV. Arbutus also laid off approximately 40% of its workforce. Both moves were made to reduce quarterly cash burn. Management projects Arbutus will burn through $47 million to $50 million of cash in FY2025, an improvement from its approximate $65 million annual cash burn rate in FY2024 before these actions were taken. ...

For further details see: